香港股市 將在 3 小時 35 分鐘 開市

Perrigo Company plc (PIG.F)

Frankfurt - Frankfurt 延遲價格。貨幣為 EUR。
加入追蹤清單
33.83-0.74 (-2.15%)
收市價: 08:23AM CET
全螢幕
前收市價34.58
開市33.83
買盤33.68 x 30000
賣出價34.26 x 30000
今日波幅33.83 - 33.83
52 週波幅28.95 - 42.65
成交量6
平均成交量1
市值4.576B
Beta 值 (5 年,每月)0.80
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-0.78
業績公佈日
遠期股息及收益率0.98 (2.87%)
除息日2022年12月01日
1 年預測目標價51.00
  • InvestorPlace

    7 Perfect Presents to Gift Your 2023 Stock Portfolio

    New Year 2023 will see a continued tightening of monetary policy as the Federal Reserve attempts to rein in sky-high inflation. Following the 50 basis point rate hike in Dec., there are expectations that Feb. and March will see 25 basis point rate hikes, respectively. That will bring target rates near 5% which is where investors should expect them to remain throughout 2023. In short, investors should expect 2023 to look and feel like 2022 in many ways. However, there are still a good deal of hot

  • Benzinga

    Perrigo Shares Fall As Investors React To Lowered FY22 Profit Guidance

    Perrigo Company plc's (NYSE: PRGO) Q3 FY22 sales increased 5.5% Y/Y or 12.3%, excluding the impact of currency translation to $1.10 billion, almost in line with the consensus of $1.10 billion. The growth was led by the acquisition of HRA, strategic pricing actions across Consumer Self-Care segments, and cough/cold-related product sales. Adjusted EPS increased 24.4% to $0.56, up from $0.45 a year ago. "Although revenue growth in the quarter was robust, it was below our estimates due to unfavorabl

  • Benzinga

    FDA Postpones Review Meeting For First OTC Contraceptive Option From Perrigo

    The FDA has pushed back a decision date on a proposed over-the-counter pill, Opill, from Perrigo Company plc's (NYSE: PRGO) subsidiary, HRA Pharma. Perrigo had previously expected approval in the first half of 2023, but the exact original FDA action date was never disclosed. Perrigo's HRA Pharma applied for the Rx-to-OTC switch on July 11, and such reviews typically take ten months. In addition to its decision delay, the FDA also postponed the planned joint meeting by its Nonprescription Drugs A